This was supposed to be a biggie in the pipeline for GSK. They can't seem to get anything right these days. Maybe the HIF inhibitor can hit it big if safety is better than FGEN and AKBA, which was not even talked about a few years ago bc it was not in one of their "core areas"? I am not surprised Hal Barron jumped ship
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.